This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
by Debanjana Dey
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic (MDT) owing to new product flow and strong market share gain across the company's businesses.
NVST or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes
by Zacks Equity Research
Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.
Boston Scientific's (BSX) New Buyout to Aid Clot Management
by Zacks Equity Research
The acquisition of Devoro Medical by Boston Scientific (BSX) is expected to advance the company's core emphasis on clot management.
Abbott's (ABT) Portico With FlexNav System Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given a strong second-quarter performance and strength in the Structural Heart business.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Abbott (ABT) Expands Vascular Portfolio With New Acquisition
by Zacks Equity Research
Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.
Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line
by Zacks Equity Research
Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.
Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable
by Zacks Equity Research
Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.
Why Is Boston Scientific (BSX) Down 1.4% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NVST vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
If You Invested $1000 in Boston Scientific 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Boston Scientific (BSX) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
NVST or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVST vs. BSX: Which Stock Is the Better Value Option?
Top Research Reports for Amazon, Pfizer & Verizon
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Pfizer Inc. (PFE), and Verizon Communications Inc. (VZ).
4 Medical Device Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.
OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.
Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.
Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.
Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.
Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.